Rapid UPLC-MS/MS method for routine analysis of plasma pristanic, phytanic, and very long chain fatty acid markers of peroxisomal disorders.
Osama Y Al-Dirbashi, Tomofumi Santa, Mohamed S Rashed, Zuhair Al-Hassnan, Nobuyuki Shimozawa, Aziza Chedrawi, Minnie Jacob, Manhal Al-Mokhadab
Index: J. Lipid Res. 49 , 1855-1862, (2008)
Full Text: HTML
Abstract
Quantification of pristanic acid, phytanic acid, and very long chain fatty acids (i.e., hexacosanoic, tetracosanoic, and docosanoic acids) in plasma is the primary method for investigateing a multitude of peroxisomal disorders (PDs). Typically based on GC-MS, existing methods are time-consuming and laborious. In this paper, we present a rapid and specific liquid chromatography tandem mass spectrometric method based on derivatization with 4-[2-(N,N-dimethylamino)ethylaminosulfonyl]-7-(2-aminoethylamino)-2,1,3-benzoxadiazole (DAABD-AE). Derivatization was undertaken to improve the poor mass spectrometric properties of these fatty acids. Analytes in plasma (20 mul) were hydrolyzed, extracted, and derivatized with DAABD-AE in approximately 2 h. Derivatives were separated on a reverse-phase column and detected by positive-ion electrospray ionization tandem mass spectrometry with a 5 min injection-to-injection time. Calibration plots were linear over ranges that cover physiological and pathological concentrations. Intraday (n = 12) and interday (n = 10) variations at low and high concentrations were less than 9.2%. Reference intervals in normal plasma (n = 250) were established for each compound and were in agreement with the literature. Using specimens from patients with established diagnosis (n = 20), various PDs were reliably detected. In conclusion, this method allows for the detection of at least nine PDs in a 5 min analytical run. Furthermore, this derivatization approach is potentially applicable to other disease markers carrying the carboxylic group.
Related Compounds
Related Articles:
2015-01-01
[Biochim. Biophys. Acta 1853(1) , 111-25, (2014)]
Peroxisomal bifunctional enzyme deficiency.
1989-03-01
[J. Clin. Invest. 83(3) , 771-7, (1989)]
2003-08-01
[Cancer Epidemiol. Biomarkers Prev. 12(8) , 775-83, (2003)]
Clinical and biochemical characteristics of peroxisomal disorders: an update.
1994-01-01
[Eur. J. Pediatr. 153(7 Suppl 1) , S44-8, (1994)]
2006-01-01
[Mol. Genet. Metab. 87(1) , 40-7, (2006)]